Koers SWEDISH ORPHAN BIOVITRUM London S.E.
Aandelen
0GY1
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- SEK | - |
|
Omzet 2024 * | 24,62 mld. 2,35 mld. 2,17 mld. | Omzet 2025 * | 27,29 mld. 2,61 mld. 2,4 mld. | Marktkapitalisatie | 94,01 mld. 8,98 mld. 8,28 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 3,44 mld. 329 mln. 303 mln. | Nettowinst (verlies) 2025 * | 4,97 mld. 475 mln. 438 mln. | EV/omzet 2024 * | 4,4 x |
Nettoschuld 2024 * | 14,44 mld. 1,38 mld. 1,27 mld. | Nettoschuld 2025 * | 8,83 mld. 843 mln. 777 mln. | EV/omzet 2025 * | 3,77 x |
K/w-verhouding 2024 * |
26,9
x | K/w-verhouding 2025 * |
18,8
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 50,9% |
Recentste transcriptie over SWEDISH ORPHAN BIOVITRUM
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 59 | 22-05-17 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 57 | 20-07-18 |
Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 68 | 01-01-21 | |
Annette Clancy
CHM | Chairman | 70 | 08-05-14 |
Staffan Schüberg
BRD | Director/Board Member | 55 | 01-01-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+4,57% | 97,7 mld. | |
+5,66% | 41,43 mld. | |
-12,80% | 32,85 mld. | |
+80,99% | 29,33 mld. | |
-15,53% | 15,47 mld. | |
-8,70% | 12,89 mld. | |
-12,22% | 11,51 mld. | |
+183,25% | 10,74 mld. | |
-55,41% | 8,97 mld. |
- Beurs
- Aandelen
- Koers SOBI
- Koers 0GY1